Photodynamic therapy for multiple primary bronchogenic carcinoma

T. Okunaka, H. Kato, C. Konaka, Norihiko Kawate, A. Bonaminio, H. Yamamoto, N. Ikeda, M. Tolentino, M. L. Eckhauser, Y. Hayata

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

In recent years, multiple primary lung cancers have been reported with greater frequency, partly as a result of technologic advances in the detection of lung cancer and therapeutic achievements in its management. Photodynamic therapy (PDT) is a relatively new therapy used with increasing frequency in the treatment of a wide variety of malignancies, including central lung cancers. In PDT, the differential retention of an injected photosensitizer by malignant tissue is exploited by treatment with a low-power laser beam delivered endoscopically. Since 1980, 145 patients with central lung cancers, including 35 cases of endoscopically evaluated early-stage lesions were treated with PDT at Tokyo Medical College. Thirteen of these 145 patients had multiple primary bronchogenic carcinomas, five cases of which were synchronous with the rest, metachronous. Three of 13 patients with multiple tumors had early-stage lesions and were treated with endoscopic PDT alone. In the other ten cases, PDT was used to treat accessible early-stage foci although operative excision was required for advanced lesions. Mean survival after PDT, alone or in combination with surgery, was 38 months (range, 14 to 87 months), and seven patients remain alive to date. It was concluded that PDT is useful in extending the therapeutic options for, and improving the prognosis of patients with, multiple primary bronchogenic carcinomas.

Original languageEnglish
Pages (from-to)253-258
Number of pages6
JournalCancer
Volume68
Issue number2
DOIs
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Bronchogenic Carcinoma
Photochemotherapy
Lung Neoplasms
Therapeutics
Photosensitizing Agents
Tokyo
Neoplasms
Lasers
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Photodynamic therapy for multiple primary bronchogenic carcinoma. / Okunaka, T.; Kato, H.; Konaka, C.; Kawate, Norihiko; Bonaminio, A.; Yamamoto, H.; Ikeda, N.; Tolentino, M.; Eckhauser, M. L.; Hayata, Y.

In: Cancer, Vol. 68, No. 2, 1991, p. 253-258.

Research output: Contribution to journalArticle

Okunaka, T, Kato, H, Konaka, C, Kawate, N, Bonaminio, A, Yamamoto, H, Ikeda, N, Tolentino, M, Eckhauser, ML & Hayata, Y 1991, 'Photodynamic therapy for multiple primary bronchogenic carcinoma', Cancer, vol. 68, no. 2, pp. 253-258. https://doi.org/10.1002/1097-0142(19910715)68:2<253::AID-CNCR2820680206>3.0.CO;2-F
Okunaka, T. ; Kato, H. ; Konaka, C. ; Kawate, Norihiko ; Bonaminio, A. ; Yamamoto, H. ; Ikeda, N. ; Tolentino, M. ; Eckhauser, M. L. ; Hayata, Y. / Photodynamic therapy for multiple primary bronchogenic carcinoma. In: Cancer. 1991 ; Vol. 68, No. 2. pp. 253-258.
@article{46a8e09ef1d14ac3b699028146cd59e1,
title = "Photodynamic therapy for multiple primary bronchogenic carcinoma",
abstract = "In recent years, multiple primary lung cancers have been reported with greater frequency, partly as a result of technologic advances in the detection of lung cancer and therapeutic achievements in its management. Photodynamic therapy (PDT) is a relatively new therapy used with increasing frequency in the treatment of a wide variety of malignancies, including central lung cancers. In PDT, the differential retention of an injected photosensitizer by malignant tissue is exploited by treatment with a low-power laser beam delivered endoscopically. Since 1980, 145 patients with central lung cancers, including 35 cases of endoscopically evaluated early-stage lesions were treated with PDT at Tokyo Medical College. Thirteen of these 145 patients had multiple primary bronchogenic carcinomas, five cases of which were synchronous with the rest, metachronous. Three of 13 patients with multiple tumors had early-stage lesions and were treated with endoscopic PDT alone. In the other ten cases, PDT was used to treat accessible early-stage foci although operative excision was required for advanced lesions. Mean survival after PDT, alone or in combination with surgery, was 38 months (range, 14 to 87 months), and seven patients remain alive to date. It was concluded that PDT is useful in extending the therapeutic options for, and improving the prognosis of patients with, multiple primary bronchogenic carcinomas.",
author = "T. Okunaka and H. Kato and C. Konaka and Norihiko Kawate and A. Bonaminio and H. Yamamoto and N. Ikeda and M. Tolentino and Eckhauser, {M. L.} and Y. Hayata",
year = "1991",
doi = "10.1002/1097-0142(19910715)68:2<253::AID-CNCR2820680206>3.0.CO;2-F",
language = "English",
volume = "68",
pages = "253--258",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Photodynamic therapy for multiple primary bronchogenic carcinoma

AU - Okunaka, T.

AU - Kato, H.

AU - Konaka, C.

AU - Kawate, Norihiko

AU - Bonaminio, A.

AU - Yamamoto, H.

AU - Ikeda, N.

AU - Tolentino, M.

AU - Eckhauser, M. L.

AU - Hayata, Y.

PY - 1991

Y1 - 1991

N2 - In recent years, multiple primary lung cancers have been reported with greater frequency, partly as a result of technologic advances in the detection of lung cancer and therapeutic achievements in its management. Photodynamic therapy (PDT) is a relatively new therapy used with increasing frequency in the treatment of a wide variety of malignancies, including central lung cancers. In PDT, the differential retention of an injected photosensitizer by malignant tissue is exploited by treatment with a low-power laser beam delivered endoscopically. Since 1980, 145 patients with central lung cancers, including 35 cases of endoscopically evaluated early-stage lesions were treated with PDT at Tokyo Medical College. Thirteen of these 145 patients had multiple primary bronchogenic carcinomas, five cases of which were synchronous with the rest, metachronous. Three of 13 patients with multiple tumors had early-stage lesions and were treated with endoscopic PDT alone. In the other ten cases, PDT was used to treat accessible early-stage foci although operative excision was required for advanced lesions. Mean survival after PDT, alone or in combination with surgery, was 38 months (range, 14 to 87 months), and seven patients remain alive to date. It was concluded that PDT is useful in extending the therapeutic options for, and improving the prognosis of patients with, multiple primary bronchogenic carcinomas.

AB - In recent years, multiple primary lung cancers have been reported with greater frequency, partly as a result of technologic advances in the detection of lung cancer and therapeutic achievements in its management. Photodynamic therapy (PDT) is a relatively new therapy used with increasing frequency in the treatment of a wide variety of malignancies, including central lung cancers. In PDT, the differential retention of an injected photosensitizer by malignant tissue is exploited by treatment with a low-power laser beam delivered endoscopically. Since 1980, 145 patients with central lung cancers, including 35 cases of endoscopically evaluated early-stage lesions were treated with PDT at Tokyo Medical College. Thirteen of these 145 patients had multiple primary bronchogenic carcinomas, five cases of which were synchronous with the rest, metachronous. Three of 13 patients with multiple tumors had early-stage lesions and were treated with endoscopic PDT alone. In the other ten cases, PDT was used to treat accessible early-stage foci although operative excision was required for advanced lesions. Mean survival after PDT, alone or in combination with surgery, was 38 months (range, 14 to 87 months), and seven patients remain alive to date. It was concluded that PDT is useful in extending the therapeutic options for, and improving the prognosis of patients with, multiple primary bronchogenic carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0025996431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025996431&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19910715)68:2<253::AID-CNCR2820680206>3.0.CO;2-F

DO - 10.1002/1097-0142(19910715)68:2<253::AID-CNCR2820680206>3.0.CO;2-F

M3 - Article

VL - 68

SP - 253

EP - 258

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -